A Phase 1, First in Man, Safety, Tolerability and Pharmacokinetic Study of Single Ascending and Multiple Cutaneous Doses of LEO 29102 2.5 mg/g Cream or LEO 29102 Cream Vehicle in Healthy Male Subjects
Latest Information Update: 28 Feb 2025
At a glance
- Drugs LEO 29102 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors LEO Pharma
Most Recent Events
- 27 Nov 2014 New trial record